Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242496110> ?p ?o ?g. }
- W4242496110 endingPage "782" @default.
- W4242496110 startingPage "782" @default.
- W4242496110 abstract "Abstract Abstract 782 Introduction: Current evidence indicates that acquired genetic instability in chronic myeloid leukemia (CML) as a consequence of the t(9;22)(q34;q11) and the resulting BCR-ABL fusion causes the continuous acquisition of additional chromosomal aberrations (ACA) and mutations and thereby progression to accelerated phase and blast crisis (BC). Around 10 –12% of patients in chronic phase (CP) CML have ACA already at diagnosis. During the course of the disease this number rises to 80% in BC. Acquisition of ACA during treatment is considered as a poor prognostic indicator, whereas the impact of ACA at diagnosis is controversial. Patients and methods: Clinical and cytogenetic data of 1151 out of 1311 patients with Philadelphia and BCR-ABL positive CP CML randomized until 2009 to the German CML-Study IV were investigated in a prospective study. There were 459 females (40%) and 692 males (60%). Median age was 53 years (range, 16–88). All patients were treated with imatinib alone or in combination with interferon alpha or araC. The impact of ACA at diagnosis on time to complete cytogenetic and major molecular remission (CCR, MMR) and progression-free and overall survival (PFS, OS) was investigated. Written informed consent was obtained from all patients prior to entering the study. Results: At diagnosis 1003/1151 patients (87%) had the standard t(9;22)(q34;q11) only and 69 patients (6.0%) had a variant t(v;22). In 60 of 69 patients with t(v;22), only one further chromosome was involved in the translocation, in 7 patients two, and in 2 patients three further chromosomes were involved. Seventy-nine patients (6.9%) had ACA. Of these, 38 patients (3.3%) lacked the Y chromosome (-Y) and 41 patients (3.6%) had ACA except -Y. Sixteen of the 41 patients had major-route ACA (+8, i(17)(q10), +der(22)t(9;22)(q34;q11), ider(22)(q10)t(9;22)(q34;q11)) and 25 minor-route ACA [e.g. t(3;12), t(4;6), t(2;16), t(1;21)]. In patients with major-route ACA, trisomy 8 was the most frequent additional alteration (n=9). +der(22)t(9;22)(q34;q11) was observed in six patients, isochromosome (17)(q10) in five patients and ider(22)(q10)t(9;22)(q34;11) in three patients. After a median observation time of 5.3 years for patients with t(9;22), t(v;22), -Y, minor- and major-route ACA median times to CCR were 1.01, 0.95, 0.98, 1.49 and 1.51 years, to MMR 1.40, 1.58, 1.65, 2.49 and > 7 years, 5-year PFS 90%, 81%, 88%, 96% and 50% and 5-year OS 92%, 87%, 91%, 96% and 53%, respectively. In patients with major-route ACA times to CCR and MMR were longer. PFS and OS were shorter (p<0.001) than with standard t(9;22)(q34;q11). Loss of Y chromosome had no influence on time to CCR or MMR, PFS and OS. Conclusion: We conclude that the prognostic impact of additional cytogenetic findings at diagnosis of CML is heterogeneous and consideration of their types may be important. Major-route ACA identify a small group of patients with significantly poorer prognosis as compared to all other patients requiring early and more intensive intervention such as stem cell transplantation. Disclosures: Hochhaus: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Ariad: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Kneba:Hoffmann La Roche: Honoraria." @default.
- W4242496110 created "2022-05-12" @default.
- W4242496110 creator A5007614326 @default.
- W4242496110 creator A5009383961 @default.
- W4242496110 creator A5013024565 @default.
- W4242496110 creator A5016147985 @default.
- W4242496110 creator A5016360607 @default.
- W4242496110 creator A5021124944 @default.
- W4242496110 creator A5021480569 @default.
- W4242496110 creator A5029332875 @default.
- W4242496110 creator A5029465235 @default.
- W4242496110 creator A5030025370 @default.
- W4242496110 creator A5031540176 @default.
- W4242496110 creator A5033935778 @default.
- W4242496110 creator A5035879639 @default.
- W4242496110 creator A5035964802 @default.
- W4242496110 creator A5044783231 @default.
- W4242496110 creator A5045429879 @default.
- W4242496110 creator A5045850647 @default.
- W4242496110 creator A5056153132 @default.
- W4242496110 creator A5056354952 @default.
- W4242496110 creator A5061380659 @default.
- W4242496110 creator A5066624700 @default.
- W4242496110 creator A5066994665 @default.
- W4242496110 creator A5067574718 @default.
- W4242496110 creator A5069437715 @default.
- W4242496110 creator A5071375810 @default.
- W4242496110 creator A5075459915 @default.
- W4242496110 creator A5085849523 @default.
- W4242496110 creator A5086462994 @default.
- W4242496110 creator A5087994379 @default.
- W4242496110 creator A5088450042 @default.
- W4242496110 date "2011-11-18" @default.
- W4242496110 modified "2023-09-30" @default.
- W4242496110 title "Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV" @default.
- W4242496110 doi "https://doi.org/10.1182/blood.v118.21.782.782" @default.
- W4242496110 hasPublicationYear "2011" @default.
- W4242496110 type Work @default.
- W4242496110 citedByCount "1" @default.
- W4242496110 countsByYear W42424961102012 @default.
- W4242496110 crossrefType "journal-article" @default.
- W4242496110 hasAuthorship W4242496110A5007614326 @default.
- W4242496110 hasAuthorship W4242496110A5009383961 @default.
- W4242496110 hasAuthorship W4242496110A5013024565 @default.
- W4242496110 hasAuthorship W4242496110A5016147985 @default.
- W4242496110 hasAuthorship W4242496110A5016360607 @default.
- W4242496110 hasAuthorship W4242496110A5021124944 @default.
- W4242496110 hasAuthorship W4242496110A5021480569 @default.
- W4242496110 hasAuthorship W4242496110A5029332875 @default.
- W4242496110 hasAuthorship W4242496110A5029465235 @default.
- W4242496110 hasAuthorship W4242496110A5030025370 @default.
- W4242496110 hasAuthorship W4242496110A5031540176 @default.
- W4242496110 hasAuthorship W4242496110A5033935778 @default.
- W4242496110 hasAuthorship W4242496110A5035879639 @default.
- W4242496110 hasAuthorship W4242496110A5035964802 @default.
- W4242496110 hasAuthorship W4242496110A5044783231 @default.
- W4242496110 hasAuthorship W4242496110A5045429879 @default.
- W4242496110 hasAuthorship W4242496110A5045850647 @default.
- W4242496110 hasAuthorship W4242496110A5056153132 @default.
- W4242496110 hasAuthorship W4242496110A5056354952 @default.
- W4242496110 hasAuthorship W4242496110A5061380659 @default.
- W4242496110 hasAuthorship W4242496110A5066624700 @default.
- W4242496110 hasAuthorship W4242496110A5066994665 @default.
- W4242496110 hasAuthorship W4242496110A5067574718 @default.
- W4242496110 hasAuthorship W4242496110A5069437715 @default.
- W4242496110 hasAuthorship W4242496110A5071375810 @default.
- W4242496110 hasAuthorship W4242496110A5075459915 @default.
- W4242496110 hasAuthorship W4242496110A5085849523 @default.
- W4242496110 hasAuthorship W4242496110A5086462994 @default.
- W4242496110 hasAuthorship W4242496110A5087994379 @default.
- W4242496110 hasAuthorship W4242496110A5088450042 @default.
- W4242496110 hasConcept C104317684 @default.
- W4242496110 hasConcept C126322002 @default.
- W4242496110 hasConcept C138626823 @default.
- W4242496110 hasConcept C143998085 @default.
- W4242496110 hasConcept C170493617 @default.
- W4242496110 hasConcept C2777583451 @default.
- W4242496110 hasConcept C2778729363 @default.
- W4242496110 hasConcept C2778904597 @default.
- W4242496110 hasConcept C3019892230 @default.
- W4242496110 hasConcept C43907098 @default.
- W4242496110 hasConcept C54355233 @default.
- W4242496110 hasConcept C71924100 @default.
- W4242496110 hasConcept C86803240 @default.
- W4242496110 hasConcept C90924648 @default.
- W4242496110 hasConceptScore W4242496110C104317684 @default.
- W4242496110 hasConceptScore W4242496110C126322002 @default.
- W4242496110 hasConceptScore W4242496110C138626823 @default.
- W4242496110 hasConceptScore W4242496110C143998085 @default.
- W4242496110 hasConceptScore W4242496110C170493617 @default.
- W4242496110 hasConceptScore W4242496110C2777583451 @default.
- W4242496110 hasConceptScore W4242496110C2778729363 @default.
- W4242496110 hasConceptScore W4242496110C2778904597 @default.
- W4242496110 hasConceptScore W4242496110C3019892230 @default.
- W4242496110 hasConceptScore W4242496110C43907098 @default.
- W4242496110 hasConceptScore W4242496110C54355233 @default.
- W4242496110 hasConceptScore W4242496110C71924100 @default.
- W4242496110 hasConceptScore W4242496110C86803240 @default.